Business
Novocure Announces 31 Presentations on Tumor Treating Fields at Society for Neuro-Oncology 2021 Annual Meeting
An oral presentation will feature updated data from the 2-THE-TOP study treating patients with newly diagnosed glioblastoma (GBM) with TTFields plus
About this update from Novocure Limited
[{"type":"text","content":"\nAn oral presentation will feature updated data from the 2-THE-TOP study treating patients with newly diagnosed glioblastoma (GBM) with TTFields plus pembrolizumab and temozolomide\n\n ST. HELIER, Jersey--(BUSINESS WIRE)--\nNovocure (NASDAQ: NVCR) today announced 31 presentations on Tumor Treating Fields (TTFields) will be featured at the Society for Neuro-Oncology (SNO) 2021 Annual Meeting from Nov. 18 to Nov. 21 in Boston. The presentations cover a broad range of topics, with 22 of the 31 presentations prepared by external authors.\n\nOne of the oral presentations will feature updated data from the 2-THE-TOP study treating 25 patients with newly diagnosed glioblastoma (GBM) with TTFields plus pembrolizumab and temozolomide. In patients with greater than 9 months of follow-up, median progression-free survival, the primary endpoint, was at least 11.2 months with activation of adaptive immunity.\n\n“We are excited to gather, participate and share information on Tumor Treating Fields at the SNO 2021 Annual Meeting, one of the most important neuro-oncology conferences worldwide,” said Dr. Ely Benaim, Novocure’s Chief Medical Officer. “More than 300 presentations on Tumor Treating Fields have been shared at SNO over the past 14 years. We look forward to driving further awareness and understanding of our therapy as an important treatment for solid tumors.”\n\nOral Presentations\n\n(CTIM-16) Phase 2 study of pembrolizumab plus TTFields plus temozolomide in patients with newly diagnosed GBM (2-THE-TOP trial). Lead author and presenter: David D. Tran. 5:05 p.m. to 5:10 p.m. EST Friday, Nov.19. (Clinical Trials Session I)\n\nInduction of anti-tumor immunity in glioblastoma using Tumor Treating Fields. Presenter: David D. Tran. 11:30 a.m. to 11:50 a.m. EST Sunday, Nov. 21. (Emerging Technologies in Radiation Science Session)\n\nPoster Presentations\n\nAll occurring 7:30 p.m. to 9:30 p.m. EST Friday, Nov. 19 in Exhibit Hall D\n\nClinical\n\n(INNV-22) Factors guiding the initiation of Tumor Treating Fields (TTFields; 200 kHz) therapy for glioblastoma: self-reported patient and oncologist perspectives. Lead author and presenter: Peggy Frongillo.\n\n(SURG-06) The safety profile of Tumor Treating Fields (TTFields; 200 kHz) concomitant with ventriculo-peritoneal shunts in patients with glioblastoma and hydrocephalus. Lead author: Nancy Ann Obe...